News
LH
206.17
-0.04%
-0.08
Morgan Stanley Sticks to Their Buy Rating for Laboratory (LH)
TipRanks · 9h ago
Weekly Report: what happened at LH last week (0708-0712)?
Weekly Report · 12h ago
Citi upgrades Illumina, Quest, Agilent to buy, downgrades Avantor
Healthcare Citi upgrades Illumina, Quest, Agilent to buy, downgrades Avantor to neutral. Citi has upgraded Illumina,. Quest Diagnostics and Agilents to buy. The bank downgraded Avantors to neutral and lowered its price target for the company.
Seeking Alpha · 5d ago
Oppenheimer’s top SMID ideas within high-growth themes
Oppenheimer’s top SMID ideas within high-growth themes. These stocks are high-conviction “SMID-cap” ideas for 2024 with a market cap of $1B to $10B. Oppenheimer research analysts outlined the top small-cap and mid-cap stocks that have exposure to several high- growth themes.
Seeking Alpha · 5d ago
Laboratory Corp. Price Target Raised to $215.00/Share From $210.00 by Evercore ISI Group
Dow Jones · 6d ago
Laboratory Corp. Is Maintained at In-Line by Evercore ISI Group
Dow Jones · 6d ago
Evercore ISI Group Maintains In-Line on Labcorp Holdings, Raises Price Target to $215
Benzinga · 6d ago
NOWDiagnostics Raises $22.5M In Series B Financing Led By DigitalDx Ventures
Benzinga · 6d ago
Here’s What to Expect From Labcorp Holdings’ Next Earnings Report
Labcorp Holdings Inc. Is expected to announce its Q2 earnings before the markets open on Thursday, August 1. The company's shares fell 4.6% despite its better-than-expected Q1 earnings results on April 25. Labcorp stock is down 10% on a YTD basis.
Barchart · 6d ago
Labcorp Holdings Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
6 analysts have published ratings on Labcorp Holdings (NYSE:LH) in the last three months. The company has an average price target of $245.67. In the last 12 months, the company has seen a 3.91% decline in its share price. The firm is one of the two largest independent clinical laboratories in the United States.
Benzinga · 07/08 17:00
Laboratory Corp. Is Maintained at Outperform by Baird
Dow Jones · 07/08 16:10
Laboratory Corp. Price Target Raised to $261.00/Share From $258.00 by Baird
Dow Jones · 07/08 16:10
Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $261
Benzinga · 07/08 16:00
Peek Under The Hood: VO Has 12% Upside
NASDAQ · 07/08 14:21
Weekly Report: what happened at LH last week (0701-0705)?
Weekly Report · 07/08 09:16
Quest Diagnostics' LifeLabs Buy Could Boost Earnings by 4% to 5% -- Market Talk
Dow Jones · 07/05 15:45
Labcorp Q2 2024 Financial Results and Conference Call Announcement
TipRanks · 07/01 14:03
Labcorp to Announce Second Quarter Financial Results on August 1, 2024
Labcorp will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024. The company will host a conference call and webcast to discuss the results. Labcorp is a global leader of innovative and comprehensive laboratory services.
PR Newswire · 07/01 11:00
Labcorp Holdings Inc.'s (NYSE:LH) Has Performed Well But Fundamentals Look Varied: Is There A Clear Direction For The Stock?
Labcorp Holdings' (NYSE:LH) stock is up by 4.4% over the past month. Return on equity or ROE is a measure of how much a company can earn for its shareholders. The company's earnings growth rate is lower than the average for its industry. Labcorp Holding has a 5.0% return on equity and is expected to grow earnings in the future. It has a high rate of return, but the company has not seen much growth in its earnings.
Simply Wall St · 07/01 10:05
Weekly Report: what happened at LH last week (0624-0628)?
Weekly Report · 07/01 09:16
More
Webull provides a variety of real-time LH stock news. You can receive the latest news about Labcorp Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.